Asymptomatic SARS-CoV-2 infection: is it all about being refractile to innate immune sensing of viral spare-parts?-Clues from exotic animal reservoirsShow others and affiliations
2021 (English)In: Pathogens and Disease, E-ISSN 2049-632X, Vol. 79, no 1, article id ftaa076Article in journal (Refereed) Published
Abstract [en]
A vast proportion of coronavirus disease 2019 (COVID-19) individuals remain asymptomatic and can shed severe acute respiratory syndrome (SARS-CoV) type 2 virus to transmit the infection, which also explains the exponential increase in the number of COVID-19 cases globally. Furthermore, the rate of recovery from clinical COVID-19 in certain pockets of the globe is surprisingly high. Based on published reports and available literature, here, we speculated a few immunovirological mechanisms as to why a vast majority of individuals remain asymptomatic similar to exotic animal (bats and pangolins) reservoirs that remain refractile to disease development despite carrying a huge load of diverse insidious viral species, and whether such evolutionary advantage would unveil therapeutic strategies against COVID-19 infection in humans. Understanding the unique mechanisms that exotic animal species employ to achieve viral control, as well as inflammatory regulation, appears to hold key clues to the development of therapeutic versatility against COVID-19.
Place, publisher, year, edition, pages
OXFORD UNIV PRESS , 2021. Vol. 79, no 1, article id ftaa076
Keywords [en]
asymptomatic; COVID-19; evolution; origin; monocytes; SARS-CoV-2
National Category
Microbiology in the medical area
Identifiers
URN: urn:nbn:se:liu:diva-173393DOI: 10.1093/femspd/ftaa076ISI: 000610017400008PubMedID: 33537740OAI: oai:DiVA.org:liu-173393DiVA, id: diva2:1529996
Note
Funding Agencies|Department of Science and Technology-Science and Engineering Research Board, Government of India [CRG/2019/006096]; Swedish Research CouncilSwedish Research Council; Knut and Alice Wallenberg/SciLifelab; Swedish International Development Cooperation Agency; SIDA SARC; VINNMER for VinnovaVinnova; Linkoping University Hospital Research Fund; Research ALF; COVID ALF; Xiamen University Malaysia Research Funding (XMUMRF) [XMUMRF/2018-C2/ILAB/0001]; Emory University CFAR grant [P30 AI050409]; NCRR/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [30 RR00165, P51OD011132]
2021-02-202021-02-202021-02-20